- Home
- SOPH vs INBX Comparison
SOPH vs INBX Comparison
Compare SOPH & INBX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SOPH | INBX |
|---|---|---|
| Founded | 2011 | 2010 |
| Country | Switzerland | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 330.4M | 430.2M |
| IPO Year | 2021 | 2020 |
Fundamental Metrics
Financial Performance| Metric | SOPH | INBX |
|---|---|---|
| Price | $4.60 | $76.61 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 1 | 2 |
| Target Price | ★ $7.00 | N/A |
| AVG Volume (30 Days) | 84.8K | ★ 241.1K |
| Earning Date | 11-04-2025 | 11-14-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $73,297,000.00 | $1,400,000.00 |
| Revenue This Year | $18.32 | $563.00 |
| Revenue Next Year | $15.61 | $230.77 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 13.66 | N/A |
| 52 Week Low | $2.58 | $10.81 |
| 52 Week High | $5.30 | $94.57 |
Technical Indicators
Market Signals| Indicator | SOPH | INBX |
|---|---|---|
| Relative Strength Index (RSI) | 48.80 | 46.16 |
| Support Level | $4.60 | $74.80 |
| Resistance Level | $4.84 | $94.57 |
| Average True Range (ATR) | 0.24 | 7.41 |
| MACD | -0.03 | -1.26 |
| Stochastic Oscillator | 15.38 | 12.80 |
Price Performance
Historical ComparisonAbout SOPH SOPHiA GENETICS SA
Sophia Genetics SA is a healthcare technology company dedicated to establishing the practice of data-driven medicine as the standard of care and for life sciences research. It has built a cloud-based SaaS platform capable of analyzing data and generating insights from complex multimodal data sets and different diagnostic modalities. The Company had a physical presence in three countries outside of its headquarters in Switzerland: France, the United States, and Brazil.
About INBX Inhibrx Inc.
Inhibrx Biosciences Inc is a clinical-stage biopharmaceutical company with a pipeline of novel biologic therapeutic candidates, developed using its proprietary modular protein engineering platforms. Its clinical pipeline of therapeutic candidates includes INBRX-109 and INBRX-106, both of which utilize their multivalent formats where the precise valency can be optimized in a target-centric way to mediate what experts consider to be the predominant agonist function.